Prime Medicine Inc (PRME) Stock Price, Quote & News

Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and peg...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 465 0013

Website: primemedicine.com

Address:

60 First Street, Cambridge, United States

3DBuilds Dec. 4 at 5:06 PM

$CRBU $CRSP $NTLA $PRME $VERV

0 · Reply

Elamenape2 Dec. 4 at 5:00 PM

$PRME Amazing to see our better half, $BEAM has essentially recovered. Prime time next!

0 · Reply

EBITDAD Dec. 4 at 4:29 PM

$PRME

0 · Reply

PorkchopSquats Dec. 4 at 4:10 PM

$PRME Volume always precedes the big reversal. While retail panic sold, big money was loading.

1 · Reply

JasonCO Dec. 4 at 4:04 PM

$PRME bust through

2 · Reply

PorkchopSquats Dec. 4 at 3:55 PM

$PRME Good volume today, already over half of the recent average daily total. Solid break of the $4 wall would be very bullish.

0 · Reply

EBITDAD Dec. 4 at 3:52 PM

$PRME cmon break 4 with legs

1 · Reply

Reanimated666 Dec. 4 at 3:45 PM

$PRME Gap up Baby

0 · Reply

arg195 Dec. 4 at 3:34 PM

$PRME bulls celebrating too soon

1 · Reply

Mcnulty_jimmy Dec. 4 at 3:29 PM

$PRME

0 · Reply

Prime Medicine to Present at 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 2:51 PM EST - 21 days ago

Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease Transcript

Nov 11, 2025, 8:00 AM EST - 23 days ago

Prime Medicine to Present at Jefferies Global Healthcare Conference

Nov 7, 2025, 10:21 AM EST - 27 days ago

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 7, 2025, 7:00 AM EST - 27 days ago

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 3, 2025, 8:01 AM EST - 4 weeks ago

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

Oct 30, 2025, 4:01 PM EDT - 4 weeks ago

Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy

Oct 7, 2025, 8:00 AM EDT - 2 months ago

Prime Medicine to Participate in Upcoming Investor Conferences

Sep 8, 2025, 5:38 PM EDT - 3 months ago

Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 8:07 PM EDT - 3 months ago

Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 7, 2025, 12:27 PM EDT - 4 months ago

PRME Revenue Misses by 73%

Aug 7, 2025, 8:00 AM EDT - 4 months ago

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 1, 2025, 4:01 PM EDT - 4 months ago

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jul 30, 2025, 9:33 PM EDT - 4 months ago

Prime Medicine Announces Pricing of Public Offering

Jul 30, 2025, 4:01 PM EDT - 4 months ago

Prime Medicine Announces Proposed Public Offering of Common Stock

Jul 16, 2025, 8:10 AM EDT - 5 months ago

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Jul 16, 2025, 7:00 AM EDT - 5 months ago

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Jul 7, 2025, 4:45 PM EDT - 5 months ago

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

May 19, 2025, 8:31 AM EDT - 7 months ago

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

May 19, 2025, 8:30 AM EDT - 7 months ago

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

May 8, 2025, 8:00 AM EDT - 7 months ago

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

Mar 20, 2025, 6:48 PM EDT - 9 months ago

Why Prime Medicine Stock Was Climbing Higher This Week

Mar 19, 2025, 2:56 PM EDT - 9 months ago

Why Prime Medicine Stock Is Soaring Today

Mar 18, 2025, 7:00 AM EDT - 9 months ago

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Feb 28, 2025, 8:00 AM EST - 9 months ago

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 24, 2025, 8:00 AM EST - 10 months ago

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Jan 30, 2025, 12:26 PM EST - 10 months ago

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Nov 26, 2024, 5:10 AM EST - 1 year ago

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

BMY

Nov 21, 2024, 4:18 AM EST - 1 year ago

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Oct 28, 2024, 10:00 AM EDT - 1 year ago

12 High-Growth Stocks That Could Deliver Parabolic Returns

ACHR APLD CRSP JOBY LUNR NTLA NVTS

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Oct 16, 2024, 9:45 AM EDT - 1 year ago

Why I Keep Buying These 14 Incredible Growth Stocks

ACHR ASPN CRSP GE HWM JOBY KTOS

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Sep 30, 2024, 6:08 PM EDT - 1 year ago

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday

Sep 30, 2024, 12:17 PM EDT - 1 year ago

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Sep 30, 2024, 8:38 AM EDT - 1 year ago

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

BMY

Sep 30, 2024, 7:01 AM EDT - 1 year ago

Prime Medicine Unveils Strategically Focused Pipeline

Aug 28, 2024, 8:15 AM EDT - 1 year ago

2 Growth Stocks That Could Make You Richer

RKLB

May 25, 2024, 4:10 AM EDT - 1 year ago

Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio

GTLB

May 13, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 12, 2024, 3:00 AM EDT - 1 year ago

Alphabet Bought Up Two Slumping Stocks

GOOG GOOGL GTLB

May 10, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

May 8, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Mar 27, 2024, 8:45 AM EDT - 1 year ago

2 Magnificent Growth Stocks With Room to Run

TLRY

Mar 1, 2024, 8:00 AM EST - 1 year ago

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024, 4:01 PM EST - 1 year ago

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Feb 14, 2024, 11:50 PM EST - 1 year ago

Prime Medicine Announces Pricing of Upsized Public Offering

Jan 28, 2024, 8:11 AM EST - 2 years ago

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

3DBuilds Dec. 4 at 5:06 PM

$CRBU $CRSP $NTLA $PRME $VERV

0 · Reply

Elamenape2 Dec. 4 at 5:00 PM

$PRME Amazing to see our better half, $BEAM has essentially recovered. Prime time next!

0 · Reply

EBITDAD Dec. 4 at 4:29 PM

$PRME

0 · Reply

PorkchopSquats Dec. 4 at 4:10 PM

$PRME Volume always precedes the big reversal. While retail panic sold, big money was loading.

1 · Reply

JasonCO Dec. 4 at 4:04 PM

$PRME bust through

2 · Reply

PorkchopSquats Dec. 4 at 3:55 PM

$PRME Good volume today, already over half of the recent average daily total. Solid break of the $4 wall would be very bullish.

0 · Reply

EBITDAD Dec. 4 at 3:52 PM

$PRME cmon break 4 with legs

1 · Reply

Reanimated666 Dec. 4 at 3:45 PM

$PRME Gap up Baby

0 · Reply

arg195 Dec. 4 at 3:34 PM

$PRME bulls celebrating too soon

1 · Reply

Mcnulty_jimmy Dec. 4 at 3:29 PM

$PRME

0 · Reply

Stonkerzzz Dec. 4 at 3:25 PM

$PRME @PorkchopSquats we miss your TA ;)

1 · Reply

hagarone Dec. 4 at 3:18 PM

$PRME 🚀

0 · Reply

Stonkerzzz Dec. 4 at 3:18 PM

$PRME woohoo, now let’s push through and stay in the 4s. Patiently waiting for 2027 tho

0 · Reply

DOGBIRD Dec. 4 at 3:18 PM

$PRME Prime time.

0 · Reply

EBITDAD Dec. 4 at 3:16 PM

$PRME

0 · Reply

Mcnulty_jimmy Dec. 4 at 3:10 PM

$PRME Daily Deion

1 · Reply

PorkchopSquats Dec. 4 at 3:10 PM

$PRME Huh, this is new.

1 · Reply

JasonCO Dec. 4 at 3:10 PM

$PRME

1 · Reply

Markus01 Dec. 4 at 2:18 PM

$PRME Prime Medicine - Volume Shelf Support Price Target: $5.17, $7.22 Consolidation hitting right at the 618 support level at $3.61 with a corresponding volume shelf, a potential launch area. The next price targets are $5.17 to challenge previous resistance/support and $7.22 at the Golden Ratio.

0 · Reply

Benpsf Dec. 4 at 2:17 PM

$PRME Prime Medicine – Supported by Volume Shelf Price Targets: $5.17 and $7.22 PRME is consolidating directly at the 0.618 support zone around $3.61, which lines up with a strong volume shelf and could act as a launch point. The next upside levels to watch are $5.17, where prior support/resistance sits, and $7.22, aligning with the Golden Ratio target.

0 · Reply

Iightning Dec. 4 at 7:13 AM

1ightning® Premium Options Alert (Actionable) Ticker: $PRME Contract: Dec 19 $3C Entry: 1.10 Exit: 2.17 Return: +97.61% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Mcnulty_jimmy Dec. 4 at 5:58 AM

$PRME

1 · Reply

Market Cap	595.69M
Revenue (ttm)	2.98M
Net Income (ttm)	-195.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,573.15%
Debt to Equity Ratio	0.00

Volume	3,508,200
Avg Vol	3,969,176
Day's Range	N/A - N/A
Shares Out	180.51M
Stochastic %K	45%
Beta	2.69
Analysts	Strong Sell
Price Target	$6.28